Table 3 PAF, cancer cases and deaths attributable to potentially modifiable risk factors in Peruvian men and women
From: Proportion of cancer cases and deaths attributable to potentially modifiable risk factors in Peru
TOPOGRAPHY | MEN | WOMEN | ||||||
|---|---|---|---|---|---|---|---|---|
PAF (%) | C.I. 95% | Cases | Deaths | PAF (%) | C.I. 95% | Cases | Deaths | |
Mouth, pharynx | 87.8 | 64.7–100.0 | 464 | 178 | 29.2 | 15.7–45.1 | 155 | 58 |
Esophagus | 69.1 | 33.6–100.0 | 186 | 174 | 40.2 | 9.3–83.6 | 32 | 29 |
Stomach | 75.8 | 33.6–100.0 | 2,526 | 2,018 | 66.3 | 25.8–100.0 | 1,968 | 1,532 |
Colorectal | 72.5 | 32.2–100.0 | 1,632 | 845 | 54.3 | 23.0–81.8 | 1,296 | 652 |
Liver | 95.7 | 75.6–100.0 | 964 | 967 | 73.7 | 57.0–91.4 | 797 | 787 |
Gallbladder | 8.1 | 3.1–13.7 | 20 | 13 | 25.6 | 9.8–42.2 | 199 | 116 |
Pancreas | 26.7 | 16.8–37.6 | 191 | 184 | 19.4 | 13.4–25.1 | 173 | 165 |
Larynx | 98.5 | 53.0–100.0 | 165 | 95 | 65.5 | 32.9–100.0 | 43 | 24 |
Lung | 97.8 | 46.7–100.0 | 1,388 | 1,256 | 41.6 | 13.2–100.0 | 611 | 542 |
Skin melanoma | 46.9 | 43.8–50.0 | 301 | 97 | 1.2 | 0.9–2.7 | 8 | 2 |
Kaposi Sarcoma | 100.0 | 96.4–100.0 | 297 | 56 | 100.0 | 96.4–100.0 | 53 | 19 |
Breast | NA | NA | NA | NA | 41.8 | 15.6–75.8 | 2,868 | 762 |
Cervix | NA | NA | NA | NA | 100.0 | 96.4–100.0 | 4,270 | 2,288 |
Endometrium | NA | NA | NA | NA | 58.0 | 34.1–81.1 | 725 | 180 |
Ovary | NA | NA | NA | NA | 8.4 | 9.0–21.6 | 106 | 66 |
Penis | 75.0 | 45.6–88.5 | 214 | 60 | NA | NA | NA | NA |
Kidney | 33.4 | 23.3–44.0 | 394 | 167 | 34.3 | 27.3–41.5 | 265 | 102 |
Bladder | 36.7 | 28.9–44.7 | 267 | 89 | 15.1 | 9.1–21.2 | 57 | 23 |
Hodgkin’s Lymphoma | 66.4 | 36.8–91.4 | 127 | 52 | 61.4 | 35.0–82.6 | 107 | 34 |
Non-Hodgkin’s Lymphoma | 70.2 | 40.5–87.7 | 1,134 | 568 | 69.2 | 39.9–86.4 | 1,050 | 437 |
Leukemias | 15.8 | 6.4–26.9 | 169 | 132 | 10.2 | 1.9–14.8 | 85 | 68 |
TOTAL | 10,439 | 6,951 | 14,868 | 7,886 | ||||